GLAXOSMITHKLINE FDA Approval NDA 021007

NDA 021007

GLAXOSMITHKLINE

FDA Drug Application

Application #021007

Documents

Letter1999-04-15
Letter2001-05-11
Letter2002-10-02
Letter2004-03-02
Letter2005-11-18
Label2001-05-11
Label2002-08-02
Label2002-10-02
Label2004-04-05
Review2004-05-26
Letter2002-02-05
Letter2002-08-02
Letter2002-02-05
Letter2002-10-02
Label1999-04-15
Label2002-10-02
Label2005-11-16
Review2004-05-26

Application Sponsors

NDA 021007GLAXOSMITHKLINE

Marketing Status

Discontinued001
Discontinued002

Application Products

001CAPSULE;ORAL50MG0AGENERASEAMPRENAVIR
002CAPSULE;ORAL150MG0AGENERASEAMPRENAVIR

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP1999-04-15
LABELING; LabelingSUPPL2AP2000-04-28
LABELING; LabelingSUPPL3AP2000-04-24
MANUF (CMC); Manufacturing (CMC)SUPPL4AP1999-12-22
LABELING; LabelingSUPPL5AP2000-12-19
EFFICACY; EfficacySUPPL6AP2001-05-11
MANUF (CMC); Manufacturing (CMC)SUPPL8AP2000-12-14
LABELING; LabelingSUPPL9AP2001-05-09
EFFICACY; EfficacySUPPL10AP2002-02-05
LABELING; LabelingSUPPL11AP2002-08-02
LABELING; LabelingSUPPL13AP2002-02-05
LABELING; LabelingSUPPL14AP2002-10-02
LABELING; LabelingSUPPL15AP2002-10-02
LABELING; LabelingSUPPL16AP2004-02-12
LABELING; LabelingSUPPL17AP2005-11-04

Submissions Property Types

ORIG1Null0
SUPPL2Null0
SUPPL3Null0
SUPPL4Null0
SUPPL5Null0
SUPPL6Null0
SUPPL8Null0
SUPPL9Null0
SUPPL10Null0
SUPPL11Null0
SUPPL13Null0
SUPPL14Null0
SUPPL15Null0
SUPPL16Null0
SUPPL17Null0

CDER Filings

GLAXOSMITHKLINE
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21007
            [companyName] => GLAXOSMITHKLINE
            [docInserts] => ["",""]
            [products] => [{"drugName":"AGENERASE","activeIngredients":"AMPRENAVIR","strength":"50MG","dosageForm":"CAPSULE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"},{"drugName":"AGENERASE","activeIngredients":"AMPRENAVIR","strength":"150MG","dosageForm":"CAPSULE;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"}]
            [labels] => [{"actionDate":"11\/04\/2005","submission":"SUPPL-17","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2005\\\/021007s017lbl.pdf\"}]","notes":""},{"actionDate":"02\/12\/2004","submission":"SUPPL-16","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2004\\\/21007slr016,21039slr016_agenerase_lbl.pdf\"}]","notes":""},{"actionDate":"10\/02\/2002","submission":"SUPPL-15","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2002\\\/21007s14s15,21039s13s14lbl.pdf\"}]","notes":""},{"actionDate":"10\/02\/2002","submission":"SUPPL-14","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2002\\\/21007s14s15,21039s13s14lbl.pdf\"}]","notes":""},{"actionDate":"08\/02\/2002","submission":"SUPPL-11","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2002\\\/21007s11,21039s10lbl.pdf\"}]","notes":""},{"actionDate":"05\/11\/2001","submission":"SUPPL-6","supplementCategories":"Efficacy","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2001\\\/N21-007SE7006_Agenerase_Prntlbl.pdf\"}]","notes":""},{"actionDate":"04\/15\/1999","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/1999\\\/21007lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"AGENERASE","submission":"AMPRENAVIR","actionType":"50MG","submissionClassification":"CAPSULE;ORAL","reviewPriority":"Discontinued","inserts":"[]","notes":">No"},{"actionDate":"AGENERASE","submission":"AMPRENAVIR","actionType":"150MG","submissionClassification":"CAPSULE;ORAL","reviewPriority":"Discontinued","inserts":"[]","notes":">No"}]
            [supplements] => 
            [actionDate] => 2005-11-04
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.